The complaint alleges that Unicycive Therapeutics misled shareholders by suppressing critical information regarding its manufacturing operations. Specifically, the suit claims the company failed to inspect its third-party vendor’s facility or verify adherence to current good manufacturing practices. This oversight allegedly left the company without a reasonable basis to claim that FDA deficiencies had been addressed.

According to the allegations, these undisclosed risks made regulatory approval of the drug OLC increasingly unlikely. Consequently, the lawsuit asserts that leadership’s public statements regarding the company’s business prospects were materially misleading. Investors interested in the matter may contact the Law Offices of Frank R. Cruz at 310-914-5007 or via email to review their legal rights and potential involvement in the class action.